Kuros Biosciences Company Top Insiders
CSBTF Stock | USD 21.40 3.90 15.42% |
Kuros Biosciences employs about 64 people. The company is managed by 10 executives with a total tenure of roughly 18 years, averaging almost 1.0 years of service per executive, having 6.4 employees per reported executive. Examination of Kuros Biosciences' management performance can provide insight into the company performance.
BSc BS Insider CEO Director |
Florence Groot Insider Head Devel |
Kuros |
Kuros Biosciences Management Team Effectiveness
The company has return on total asset (ROA) of (0.0667) % which means that it has lost $0.0667 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1409) %, meaning that it generated substantial loss on money invested by shareholders. Kuros Biosciences' management efficiency ratios could be used to measure how well Kuros Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.Kuros Biosciences Workforce Comparison
Kuros Biosciences AG is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 243,364. Kuros Biosciences adds roughly 64.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
The company has Profit Margin (PM) of (0.74) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.64) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.64. Kuros Biosciences Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Kuros Biosciences Price Series Summation is a cross summation of Kuros Biosciences price series and its benchmark/peer.
Kuros Biosciences Notable Stakeholders
A Kuros Biosciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Kuros Biosciences often face trade-offs trying to please all of them. Kuros Biosciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Kuros Biosciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Philippe Saudan | Chief Scientific Officer and VP | Profile | |
BSc BS | CEO Director | Profile | |
Florence Groot | Head Devel | Profile | |
Oliver Kronenberg | Legal Counsel | Profile | |
MS DO | VP Affairs | Profile | |
Christopher Fair | Chief Officer | Profile | |
MBA MBA | Chief Officer | Profile | |
Alistair Irvine | Member of the Management Board, Chief Business Officer | Profile | |
Charlie Campion | VP Sales | Profile | |
John Griffin | VP Sales | Profile |
About Kuros Biosciences Management Performance
The success or failure of an entity such as Kuros Biosciences often depends on how effective the management is. Kuros Biosciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Kuros management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Kuros management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. KUROS BIOSCIENCES operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 58 people.
Kuros Biosciences Workforce Analysis
Traditionally, organizations such as Kuros Biosciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Kuros Biosciences within its industry.Kuros Biosciences Manpower Efficiency
Return on Kuros Biosciences Manpower
Revenue Per Employee | 215.9K | |
Revenue Per Executive | 1.4M | |
Net Loss Per Employee | 117.8K | |
Net Loss Per Executive | 754.1K | |
Working Capital Per Employee | 250K | |
Working Capital Per Executive | 1.6M |
Complementary Tools for Kuros Pink Sheet analysis
When running Kuros Biosciences' price analysis, check to measure Kuros Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kuros Biosciences is operating at the current time. Most of Kuros Biosciences' value examination focuses on studying past and present price action to predict the probability of Kuros Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kuros Biosciences' price. Additionally, you may evaluate how the addition of Kuros Biosciences to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |